Cyclophosphamide pharmacokinetics in children

British Journal of Clinical Pharmacology

Volumn 41, Issue 1, 1996, Pages 13-19

  Yule, S M ^a,b   Boddy, A V ^a   Cole, M ^a   Price, L ^a   Wyllie, R ^a   Tasso, M J ^a   Pearson, A D J ^a   Idle, J R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cyclophosphamide; Drug interactions; Pharmacokinetics; Variation

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALLOPURINOL; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG METABOLITE; ETOPOSIDE; FLUCONAZOLE; PREDNISOLONE; RANITIDINE;

ADOLESCENT; ARTICLE; CANCER; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; INFANT; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0030045849     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00153.x     Document Type: Article

References (49)

1. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In Principles and practice of paediatric oncology, eds Pizzo PA, Poplack DG. Philadelphia: J P Lipincott, 1989: 165-207.
2. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumour response. J Clin Oncol 1992; 10: 995-1000.
3. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W. Plasma Half-Life and urinary excretion of cyclophosphamide in children. Can Treat Rep 1990; 64: 1061-1066.
4. Juma FD, Koech DK, Kasili EG, Ogada T. Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma. Br J Clin Pharmacol 1984; 18: 106-107.
5. Tasso MJ, Boddy AV, Price L, Wyllie RA, Pearson ADJ, Idle JR. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Can Chem Pharmacol 1992; 30: 207-211.
6. 14C Cyclophosphamide: Comparative drug metabolism studies on African and American patients with lymphosarcoma and Burkitts tumour. Prog Antimicrob Antican Chemother 1970; 2: 218-225.
7. Sladek NE. Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res 1971; 31: 901-908.
8. Farrell GC, Cooksley WGE, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolising enzymes. Clin Pharmacol Ther 1979; 26: 483-492.
9. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346-352.
10. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993; 57: 129-160.
11. Homeida M, Karrar ZA, Roberts CJC. Drug metabolism in malnourished children: a study with antipyrine. Arch Dis Child 1979; 54: 299-302.
12. Alvares AP, Kapelner S, Sassa S, Kappas A. Drug metabolism in normal children, lead-poisoned children and normal adults. Clin Pharmacol Ther 1975; 17: 179-183.
13. Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE. Age related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991; 50: 132-140.
14. Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972; 32: 2761-2764.
15. Faber OK, Mouridsen HT, Skovsted L. The biotransformation of cyclophosphmide in man: Influence of prednisolone. Acta Pharmacol Toxicol 1974; 35: 195-200.
16. Faber OK, Mouridsen HT, Skovsted L. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. Br J Clin Pharmacol 1975; 2: 281-285.
17. Sladek NE, Domeyer BE, Merriman RL, Brophy GT. Differential effects of Walker 256 carcinosarcoma cells growing subcutaneously, intramuscularly or intraperitoneally on hepatic microsomal mixed-function oxygenase activity. Drug Met Dispos 1978; 6: 412-417.
18. Hadidi AFA, Idle JR. Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites. J Chromatogr 1988; 427: 121-130.
19. D'Argenio DZ, Schumitzky A. Adapt II Users Guide. Biomedical Stimulations resource, University of Southern California, LA. 1992.
20. Peck CC, Sheiner LB, Nichols AI. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev 1984; 15: 133-148.
21. Bagley CM Jnr, Bostick FW, DeVita VJ Jnr. Clinical pharmacokinetics of cyclophosphamide. Cancer Res 1973; 33: 226-233.
22. Juma FD, Rogers HJ, Trounce JR. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 1979; 8: 455-458.
23. Juma FD, Rogers HJ, Trounce JR. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nornitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 1980; 10: 327-335.
24. Juma FD, Ogada T. Pharmacokinetics of cyclophosphamide in Kenyan africans. Br J Clin Pharmacol 1983; 16: 61-63.
25. Powis G, Reece P, Ahmann DL, Ingle JN. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Can Chem Pharmacol 1987; 20: 219-222.
26. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-355.
27. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
28. Walker D, Ranu HK, Pearson ADJ, Idle JR. Cytochrome P4503A5 (CYP3A5) makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proc Am Assoc Cancer Res 1995; 36: Abstract No 2224.
29. Yamano S, Nhamburo PT, Aoyama T, et al. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: Identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 1989; 28: 7340-7348.
30. Furuya H, Meyer UA, Gelboin HV, Gonzalez FJ. Polymerase chain reaction-directed identification, cloning and quantification of human CYP2C12 mRNA. Mol Pharmacol 1991; 40: 69-79.
31. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 invovled in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
32. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P450 hPCN3, a novel cytochrome P450IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 1989; 264: 10388-10395.
33. Renwick AG, Robertson DRC, Macklin B, Challenor V, Waller DG, George CF. The pharmacokinetics of nifedipine-a population study. Br J Clin Pharmacol 1988; 25: 701-709.
34. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990; 48: 120-129.
35. Allen LM, Creaven PJ, Nelson R. Studies on the human pharmacokinetics of isophosphamide (NSC 109724). Cancer Treat Rep 1976; 60: 451-458.
36. Mouridsen HT, Faber O, Skovsted L. The metabolism of cyclophosphamide. Dose dependancy and the effect of long term treatment with cyclophosphamide. Cancer 1976; 37: 665-670.
37. Brock N, Gross R, Hohorst H-J, Klein HO, Schneider B. Activation of cyclophosphamide in man and animals. Cancer 1971; 27: 1512-1529.
38. Wilkinson PM, O'Neill PA, Thatcher N, Lucas SB. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogcnic carcinoma. Can Chem Pharmacol 1983; 11: 196-199.
39. Chan KK, Hong PS, Tutsch K, Trump DL. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 1994; 54: 6421-6429.
40. Chen T-L, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55: 810-816.
41. Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984; 26: 591-593.
42. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1981; 19: 443-451.
43. Edwards G, Calvert RT, Crowther D, Bramwell V, Scarffe H. The disposition of cyclohosphamide in a group of myeloma patients. Can Chem Pharmacol 1979; 3: 253-259.
44. Vessell ES, Passananti T, Greene FE. Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med 1970; 27: 1484-1488.
45. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GH, Guzelian PS. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 1985; 82: 6310-6314.
46. Morita K, Konishi H, Shimakawa H. Fluconazole: A potent inhibitor of cytochrome P450 dependant drug metabolism in mice and humans in vivo. Comparative study with ketoconazole. Chem Pharmacol Bull 1992; 40: 1247-1251.
47. Stevenson IH, O'Malley K, Turnbull MJ, Ballinger BR. The effect of chlorpromazine on drug metabolism. J Pharm Pharmacol 1972; 24: 577-583.
48. Wolf CR, Miles JS, Gough A, Spur NK. Molecular genetics of the human cytochrome P-450 system. Biochem Soc Trans 1990; 18: 21-24.
49. Shaw PM, Barnes TS, Cameron D, et al. Purification and characterisation of an anticonvulsant induced human cytochrome P450 cataysing cyclosporin metabolism. Biochem J 1989; 263: 653-663.